Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Brain serotonin transporter binding in former users of MDMA ('ecstasy').

Selvaraj S, Hoshi R, Bhagwagar Z, Murthy NV, Hinz R, Cowen P, Curran HV, Grasby P.

Br J Psychiatry. 2009 Apr;194(4):355-9. doi: 10.1192/bjp.bp.108.050344.

2.

Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective.

Thomasius R, Zapletalova P, Petersen K, Buchert R, Andresen B, Wartberg L, Nebeling B, Schmoldt A.

J Psychopharmacol. 2006 Mar;20(2):211-25. Review.

PMID:
16510479
3.

The effects of ecstasy on neurotransmitter systems: a review on the findings of molecular imaging studies.

Vegting Y, Reneman L, Booij J.

Psychopharmacology (Berl). 2016 Oct;233(19-20):3473-501. doi: 10.1007/s00213-016-4396-5. Epub 2016 Aug 28. Review.

4.

Neuroimaging research in human MDMA users: a review.

Cowan RL.

Psychopharmacology (Berl). 2007 Jan;189(4):539-56. Epub 2006 Jul 18. Review.

PMID:
16847678
5.

Neuroimaging findings with MDMA/ecstasy: technical aspects, conceptual issues and future prospects.

Reneman L, de Win MM, van den Brink W, Booij J, den Heeten GJ.

J Psychopharmacol. 2006 Mar;20(2):164-75. Review.

PMID:
16510475
6.

Toxicodynamics and long-term toxicity of the recreational drug, 3, 4-methylenedioxymethamphetamine (MDMA, 'Ecstasy').

Ricaurte GA, McCann UD, Szabo Z, Scheffel U.

Toxicol Lett. 2000 Mar 15;112-113:143-6. Review.

PMID:
10720723
7.

Adverse reactions with 3,4-methylenedioxymethamphetamine (MDMA; 'ecstasy').

McCann UD, Slate SO, Ricaurte GA.

Drug Saf. 1996 Aug;15(2):107-15. Review.

PMID:
8884162
8.

Meta-analysis of molecular imaging of serotonin transporters in ecstasy/polydrug users.

Roberts CA, Jones A, Montgomery C.

Neurosci Biobehav Rev. 2016 Apr;63:158-67. doi: 10.1016/j.neubiorev.2016.02.003. Epub 2016 Feb 6. Review.

9.

How strong is the evidence that brain serotonin neurons are damaged in human users of ecstasy?

Kish SJ.

Pharmacol Biochem Behav. 2002 Apr;71(4):845-55. Review.

PMID:
11888575
10.
11.

MDMA, serotonergic neurotoxicity, and the diverse functional deficits of recreational 'Ecstasy' users.

Parrott AC.

Neurosci Biobehav Rev. 2013 Sep;37(8):1466-84. doi: 10.1016/j.neubiorev.2013.04.016. Epub 2013 May 6. Review.

PMID:
23660456
12.

The confounding problem of polydrug use in recreational ecstasy/MDMA users: a brief overview.

Gouzoulis-Mayfrank E, Daumann J.

J Psychopharmacol. 2006 Mar;20(2):188-93. Review.

PMID:
16510477
13.

Functional Magnetic Resonance Imaging in Abstinent MDMA Users: A Review.

Garg A, Kapoor S, Goel M, Chopra S, Chopra M, Kapoor A, McCann UD, Behera C.

Curr Drug Abuse Rev. 2015;8(1):15-25. Review.

PMID:
25731754
14.

The role of metabolism in 3,4-(+)-methylenedioxyamphetamine and 3,4-(+)-methylenedioxymethamphetamine (ecstasy) toxicity.

Monks TJ, Jones DC, Bai F, Lau SS.

Ther Drug Monit. 2004 Apr;26(2):132-6. Review.

PMID:
15228153
15.

Altered states: the clinical effects of Ecstasy.

Cole JC, Sumnall HR.

Pharmacol Ther. 2003 Apr;98(1):35-58. Review.

PMID:
12667887
16.

The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy").

Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI.

Pharmacol Rev. 2003 Sep;55(3):463-508. Epub 2003 Jul 17. Review.

17.

Human psychobiology of MDMA or 'Ecstasy': an overview of 25 years of empirical research.

Parrott AC.

Hum Psychopharmacol. 2013 Jul;28(4):289-307. doi: 10.1002/hup.2318. Review.

PMID:
23881877
19.
20.

[Acute and long-term effects of ecstasy].

Salzmann J, Marie-Claire C, Noble F.

Presse Med. 2004 Oct 23;33(18 Suppl):24-32. Review. French.

PMID:
15617173

Supplemental Content

Support Center